Ardelyx appoints Reginald Seeto as COO
Dr. Seeto brings over a decade of pharmaceutical industry experience in corporate development, strategic operations and global marketing.
Prior to joining the company, Dr. Seeto spent eight years in roles of increasing responsibility at AstraZeneca and MedImmune, the Biologics Division of AstraZeneca, most recently serving as vice president, head of partnering and strategy for AstraZeneca.
Earlier, Dr. Seeto served as company president of AstraZeneca Thailand and before that, as executive vice president of corporate development and strategy for MedImmune.
Prior to joining AstraZeneca/MedImmune, Dr. Seeto held senior marketing roles at Organon Biosciences, which was acquired by Schering Plough in 2007, and Boehringer Ingelheim Pharmaceuticals.
He served as an engagement manager for McKinsey & Company and started his career as a practicing medical doctor and researcher in Australia.
Dr. Seeto has published several publications in peer-reviewed journals, including publications focused on his work in gastrointestinal research.
He earned both his B.S. and MBBS in medical studies from the University of Sydney, Australia. ■
LATEST MOVES FROM California
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
- CareDx appoints Michael Bell as CFO
- Visa appoints John F. Lundgren as director
More inside POST